Page last updated: 2024-12-07

o-demethyltramadol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

O-demethyltramadol: one of the major metabolites of tramadol; structure given in first source; RN given refers to parent compound [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID130829
CHEMBL ID4650315
SCHEMBL ID57246
SCHEMBL ID12125413
MeSH IDM0215263
PubMed CID9838803
CHEMBL ID201556
CHEMBL ID1400
CHEBI ID165221
SCHEMBL ID2517055
MeSH IDM0215263

Synonyms (63)

Synonym
o-demethyltramadol
phenol, m-(2-(dimethylaminomethyl)-1-hydroxycyclohexyl)-
m-(2-(dimethylaminomethyl)-1-hydroxycyclohexyl)phenol
cyclohexanol, 1-(m-hydroxyphenyl)-2-(dimethylaminomethyl)-
73986-53-5
AKOS015962236
FT-0604404
SCHEMBL57246
o-desmethyl-cis-tramadol
UWJUQVWARXYRCG-UHFFFAOYSA-N
SCHEMBL12125413
3-[2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol
phenol, 3-[2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]-
3-(2-((dimethylamino)methyl)-1-hydroxycyclohexyl)phenol
tramadol-m o-desmethyl
DTXSID40894102
o-desmethyl tramadol hcl
Q1949486
o-demethly tramadol
CHEMBL4650315
NCGC00165941-01
CHEBI:165221
o-desmethyltramadol
3-[(1r,2r)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol
80456-81-1
o-desmethyl tramadol
CHEMBL201556 ,
CHEMBL1400 ,
3-((1r,2r)-2-((dimethylamino)methyl)-1-hydroxycyclohexyl)phenol
bdbm50176258
rel-3-((1r,2r)-2-((dimethylamino)methyl)-1-hydroxycyclohexyl)phenol
bdbm50176263
3-{(1r,2r)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl}phenol
tramadol m1 metabolite
mono-o-demethyltramadol
phenol, 3-(2-((dimethylamino)methyl)-1-hydroxycyclohexyl)-, cis-(+/-)-
2wa8f50c3f ,
unii-2wa8f50c3f
o-dsmt
tramadol hydrochloride impurity d [ep impurity]
desmetramadol [who-dd]
(rr,ss)-3-(2-((dimethylamino)methyl)-1-hydroxycyclohexyl)phenol
desmetramadol
rac-3-((1r,2r)-2-((dimethylamino)methyl)-1-hydroxycyclohexyl)phenolc
desmetramadol [inn]
phenol, 3-((1r,2r)-2-((dimethylamino)methyl)-1-hydroxycyclohexyl)-, rel-
144830-14-8
SCHEMBL2517055
(+)-o-desmethyltramadol
AKOS030241093
UWJUQVWARXYRCG-HIFRSBDPSA-N
phenol, 3-((1r,2r)-2-((dimethylamino)methyl)-1-hydroxycyclohexyl)-
(+)-o-demethyltramadol
desmetramadol, cis-(+)-
9W28LW2ET5 ,
desmetramadol, r,r-(+)-
phenol, 3-(2-((dimethylamino)methyl)-1-hydroxycyclohexyl)-, (1r-cis)-
Q63395330
unii-9w28lw2et5
3-[(1r,2r)-2-[(dimethylamino)methyl]-1-hydroxy-cyclohexyl]phenol
80456-81-1 (free base)
DTXSID901313651
DTXSID401044548

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Tramadol is generally considered to be devoid of any serious adverse effects of traditional opioid receptor agonists, such as respiratory depression and drug dependence."( Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer.
Allorge, D; Broly, F; Elkalioubie, A; Fourrier, F; Garat, A; Robriquet, L; Wiart, JF, 2011
)
0.37
" In the absence of CYP inhibition (trial A), 20 mg desmetramadol and 50 mg tramadol dosed every 6 hours gave equivalent steady-state (+)-M1, similar adverse events, and analgesia significantly greater than placebo, but equal to each other."( Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials.
Johnson, MS; Kahn, SJ; Maeda, DY; Schuler, AD; Searle, SL; Webster, LR; Zebala, JA, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacodynamic endpoints evaluated were respiratory depression, measured as the change in arterial blood pCO(2), pO(2), and pH levels; and antinociception, measured by the tail-flick technique."( Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol, in rats.
Calvo, R; Garrido, MJ; Pavón, JM; Trocóniz, IF; Valle, M, 2000
)
0.31
" All pharmacokinetic variables were evaluated using a non-compartmental model."( Pharmacokinetics of tramadol in children after i.v. or caudal epidural administration.
Booker, PD; Lintz, W; Murray, A; Murthy, BV; Pandya, KS; Terlinden, R, 2000
)
0.31
" The differences were significant in the main pharmacokinetic parameters between (+)-trans-T and (-)-trans-T except Tmax."( Pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in human subjects.
Hou, YN; Liu, HC; Liu, TJ; Yang, YY, 2001
)
0.54
" The pharmacokinetic stereoselectivity of M1 was different among human subjects."( Pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in human subjects.
Hou, YN; Liu, HC; Liu, TJ; Yang, YY, 2001
)
0.54
" All pharmacokinetic parameters but Tmax of the two enantiomers of trans-T were significantly different in both sex rats."( Gender-related differences in pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in rats.
Jin, SM; Liu, HC; Wang, YL, 2003
)
0.53
" The values of Cmax for the enantiomers of trans-T and M1, and AUC0- infinity for (-)-trans T, (+)-M1, and (-)-M1 were higher in females than in males."( Pharmacokinetics of the enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in healthy male and female chinese volunteers.
Hong-Yuan, X; Hui-Chen, L; Jian-Fang, L; Ming, D; Na, W; Yang, Y, 2004
)
0.55
" A simultaneous pharmacokinetic model describing the plasma concentration-curves of the generated metabolites and the parent compounds after intravenous and oral drug administration is developed and presented."( Stereoselective pharmacokinetic analysis of tramadol and its main phase I metabolites in healthy subjects after intravenous and oral administration of racemic tramadol.
Azanza, JR; Campanero, MA; Cardenas, E; García Quetglas, E; Sádaba, B, 2007
)
0.34
" The related pharmacokinetic parameters such as C(max), T(max), AUC((0-t)), AUC((0-infinity)), T(1/2) and Cl/F were calculated and compared between the two genders."( Pharmacokinetics of tramadol and its three main metabolites in healthy male and female volunteers.
Ardakani, YH; Rouini, MR, 2007
)
0.34
" administration, the apparent volume of distribution of the central compartment, the apparent volume of distribution at steady-state, the clearance, and the terminal half-life (mean +/- SEM) were 1553+/-118 mL/kg, 3103+/-132 mL/kg, 20."( Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats.
Ilkiw, JE; Pypendop, BH, 2008
)
0.35
" In conclusion, pharmacokinetic differences between EMs and UMs were smaller than expected; nevertheless, UMs were more sensitive to tramadol than EMs."( Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
Bauer, S; Brockmöller, J; Keulen, JT; Kirchheiner, J; Roots, I, 2008
)
0.35
" The findings suggest that the SR formulation of tramadol may not have suitable pharmacokinetic characteristics to be administered once-a-day as an effective and safe treatment for pain in the dog."( Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study.
Giorgi, M; Kowalski, C; Lebkowska-Wieruszewska, B; Saccomanni, G, 2009
)
0.35
" Mean +/- SD half-life of tramadol after administration was 145."( Pharmacokinetics of orally administered tramadol in domestic rabbits (Oryctolagus cuniculus).
Cox, SK; Greenacre, CB; Souza, MJ, 2008
)
0.35
" Pharmacodynamic evaluations were performed at the time of patient sampling and included assessment of sedation, and evaluation for depression of heart and respiratory rates."( Pharmacokinetics of intravenous tramadol in dogs.
Clark, CR; Dowling, PM; Duke, T; Livingston, A; McMillan, CJ; Taylor, SM; Terlinden, R, 2008
)
0.35
" The aim of this study was to develop a population pharmacokinetic model for the (+)- and (-)-enantiomers of tramadol and its O-demethyl tramadol metabolite (M1) in children."( Population pharmacokinetics of the two enantiomers of tramadol and O-demethyl tramadol after surgery in children.
Bressolle, F; Capdevila, X; Dadure, C; Khier, S; Ouaki, J; Rochette, A, 2009
)
0.35
"To compare the rectal and I/V administration of tramadol in dogs, to assess both its pharmacokinetic properties and absolute bioavailability."( Pharmacokinetics of tramadol and its major metabolites following rectal and intravenous administration in dogs.
Del Carlo, S; Giorgi, M; Kowalski, CJ; Saccomanni, G; Łebkowska-Wieruszewska, B, 2009
)
0.35
"In the dog, rectal pharmaceutical formulation of tramadol would have a different pharmacokinetic behaviour than in humans."( Pharmacokinetics of tramadol and its major metabolites following rectal and intravenous administration in dogs.
Del Carlo, S; Giorgi, M; Kowalski, CJ; Saccomanni, G; Łebkowska-Wieruszewska, B, 2009
)
0.35
"The main pharmacokinetic parameters of tramadol and its metabolite O-demethyltramadol (M(1)) in groups 1 and 2 were not significantly different."( Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers.
Guo, Y; Li, Q; Wang, R; Wang, S; Wen, S; Xu, L, 2010
)
0.6
" The method developed and validated here was applied to a pharmacokinetic study in rats."( Simultaneous analysis of tramadol, O-desmethyltramadol, and N-desmethyltramadol enantiomers in rat plasma by high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics.
Carvalho, TM; De Moraes, NV; Godoy, AL; Lanchote, VL; Marques, MP; Martinez, EZ, 2011
)
0.37
"The aim of this investigation was to demonstrate that nonlinear mixed-effects population pharmacokinetic (PK) modeling can be used to evaluate data from studies of drug transport/excretion into human milk and hence to estimate infant exposure."( Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk.
Ilett, KF; Paech, MJ; Page-Sharp, M; Salman, S; Sy, SK, 2011
)
0.37
" Pharmacokinetic analyses were performed using non-compartmental methods."( Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
Cai, L; Cai, XJ; Jiang, B; Lv, XQ; Wang, GX; Xu, J; Xu, YY; Zhang, XC, 2014
)
0.4
" The association between genetic polymorphisms in CYP2D6, OPRM1 and ABCB1 and pharmacokinetic and pharmacodynamic properties of TRA was studied."( Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.
Bastami, S; Haage, P; Kronstrand, R; Kugelberg, FC; Uppugunduri, S; Zackrisson, AL, 2014
)
0.4
" The objective of this study was to determine the pharmacokinetic parameters of tramadol and its primary metabolite, O-desmethyltramadol (M1), after oral administration of tramadol hydrochloride (HCl) in African penguins (Spheniscus demersus)."( Pharmacokinetics of tramadol and its primary metabolite O-desmethyltramadol in African penguins (Spheniscus demersus).
Bronson, E; Cox, SK; Kilburn, JJ; Kottyan, J; Wack, AN, 2014
)
0.4
"The serum pharmacokinetic profile and urinary excretion of tramadol and its metabolites (O-desmethyltramadol [M1], N-desmethyltramadol [M2] and N,O-desmethyltramadol [M5]) was investigated in a multidrug anaesthetic and analgesic approach for orchiectomy in horses."( Clinical pharmacokinetics of tramadol and main metabolites in horses undergoing orchiectomy.
Cagnardi, P; Ferraresi, C; Pecile, A; Ravasio, G; Villa, R; Zani, DD; Zonca, A, 2014
)
0.4
" A population pharmacokinetic analysis was performed using a two-compartment model for tramadol and two additional M1 compartments."( Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study.
Allegaert, K; Anderson, BJ; Beier, H; de Hoon, JN; Holford, N; Holford, S; Pedersen, RS; Rochette, A; Stamer, U; Stuber, F; Trocóniz, IF, 2015
)
0.42
" This study aimed to evaluate the pharmacokinetic profiles of an SR 75-mg tramadol/650-mg acetaminophen formulation after a single dose compared with an immediate release (IR) 37."( An assessment of the pharmacokinetics of a sustained-release formulation of a tramadol/acetaminophen combination in healthy subjects.
Chae, SW; Im, YJ; Jeon, JY; Kim, EY; Kim, MG; Kim, Y; Oh, DJ; Shin, DH; Yoo, JS, 2015
)
0.42
"Two clinical trials were conducted: (1) an open-label, randomized, 3-period, 3-treatment, crossover study to assess the pharmacokinetic SR (one 75-mg tramadol/650-mg acetaminophen combination tablet) formulation profiles after a single dose and IR (one 37."( An assessment of the pharmacokinetics of a sustained-release formulation of a tramadol/acetaminophen combination in healthy subjects.
Chae, SW; Im, YJ; Jeon, JY; Kim, EY; Kim, MG; Kim, Y; Oh, DJ; Shin, DH; Yoo, JS, 2015
)
0.42
" After oral administration, the half-life of tramadol administered at 5 and 10 mg/kg was 20."( PHARMACOKINETICS OF TRAMADOL AND O-DESMETHYLTRAMADOL IN LOGGERHEAD SEA TURTLES (CARETTA CARETTA).
Cox, S; Hupp, A; Kaylor, M; Nelson, SE; Norton, TM; Sladky, KK; Thomas, R, 2015
)
0.42
" Pharmacokinetic parameters fitted a two- and a non-compartmental model for tramadol and M1, respectively."( Pharmacokinetics and antinociceptive effects of tramadol and its metabolite O-desmethyltramadol following intravenous administration in sheep.
Bortolami, E; De Benedictis, GM; Della Rocca, G; Di Salvo, A; Giorgi, M; Isola, M; Kim, TW, 2015
)
0.42
" Blood samples were collected for pharmacokinetic analysis of study drugs and their metabolites over an 8-hour period beginning after the second dose of the study medication."( Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy.
Benitez, ME; KuKanich, B; McMurphy, R; Roush, JK, 2015
)
0.42
" The terminal half-life for hydrocodone was 15."( Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy.
Benitez, ME; KuKanich, B; McMurphy, R; Roush, JK, 2015
)
0.42
" Pharmacodynamic studies are warranted to determine if tramadol provides analgesic effects in this species."( PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE AND ITS METABOLITE O-DESMETHYLTRAMADOL FOLLOWING A SINGLE, ORALLY ADMINISTERED DOSE IN CALIFORNIA SEA LIONS (ZALOPHUS CALIFORNIANUS).
Barbosa, L; Boonstra, JL; Cox, SK; Gulland, FM; Johnson, SP; Martin-Jimenez, T; Van Bonn, WG, 2015
)
0.42
" Samples were analyzed with LC-MS/MS and the pharmacokinetic correlations between matrices were investigated."( First report on the pharmacokinetics of tramadol and O-desmethyltramadol in exhaled breath compared to plasma and oral fluid after a single oral dose.
Beck, O; Meyer, MR; Rosenborg, S; Stenberg, M, 2015
)
0.42
"Tramadol is frequently used in geriatric patients; however, pharmacokinetic (PK) publications on tramadol and O-desmethyltramadol (ODM) in elderly patients are rare."( Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects.
Bouchard, S; Fradette, C; Mouksassi, MS; Skinner-Robertson, S; Varin, F, 2015
)
0.42
" The population analysis identified age as a covariate of V/F (young 305 L; elderly 426 L), with a 50% longer mean elimination half-life in the elderly."( Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects.
Bouchard, S; Fradette, C; Mouksassi, MS; Skinner-Robertson, S; Varin, F, 2015
)
0.42
" There was not a significant difference in the elimination half-life between age groups (1."( Effects of age on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol following intravenous administration to foals.
Knych, HK; McKemie, DS; Steffey, EP; White, AM, 2016
)
0.43
"1) At the dose administered, high plasma concentrations of tramadol and M1 were obtained, with half-life depending on the administration route."( Preliminary pharmacokinetics of tramadol hydrochloride after administration via different routes in male and female B6 mice.
Arras, M; Avenel, F; Bergadano, A; Draganov, DI; Evangelista Vaz, R; Rapp, C; Steiner, G, 2018
)
0.48
" This study describes the pharmacokinetic profile of tramadol when a single subcutaneous bolus of 2 mg/kg was initially administered to two koalas."( Pharmacokinetic profile of injectable tramadol in the koala (Phascolarctos cinereus) and prediction of its analgesic efficacy.
Govendir, M; Kimble, B; Valtchev, P; Vogelnest, L, 2021
)
0.62
" Both primary and secondary pharmacokinetic parameters were similar."( Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies.
Bujalska-Zadrożny, M; Buś-Kwaśnik, K; Filist, M; Gilant, E; Jarus-Dziedzic, K; Leś, A; Nagraba, Ł; Rudzki, PJ; Sasinowska-Motyl, M, 2021
)
0.62
" A physiologically based pharmacokinetic model for tramadol and O-desmethyltramadol was developed and verified in PK-Sim version 8 and linked to respective models of quinidine and metoprolol to evaluate the impact of allosteric and competitive CYP2D6 inhibition on tramadol and O-desmethyltramadol exposure."( Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
Cicali, B; Cristofoletti, R; Dow, P; Long, T; Michaud, V; Schmidt, S; Turgeon, J, 2022
)
0.72
"5 mg/kg to treat severe pain in children but the assay for tramadol in plasma samples for pharmacokinetic and toxicology studies does not often consider concurrently administered medications."( HPLC-UV assay of tramadol and O-desmethyltramadol in human plasma containing other drugs potentially co-administered to participants in a paediatric population pharmacokinetic study.
Hua, AJ; Lim, LY; Nguyen, MN; Salman, S; Tang, EKY; von Ungern Sternberg, BS; Yoo, O, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
"The aim of this study was to compare the pharmacokinetic profile and oral bioavailability of Tramadol Contramid once-daily (o."( Comparative bioavailability between two Tramadol once-daily oral formulations.
Encina, G; Hernandez-Lopez, C; Karhu, D; Martinez-Farnos, L; Perez-Campos, T; Rovira, S,
)
0.13
" The absolute bioavailability of tramadol via rectal administration was 10 (SD 4)%."( Pharmacokinetics of tramadol and its major metabolites following rectal and intravenous administration in dogs.
Del Carlo, S; Giorgi, M; Kowalski, CJ; Saccomanni, G; Łebkowska-Wieruszewska, B, 2009
)
0.35
" A one-compartment population model of total tramadol concentration was parameterized with clearance (CL/F), volume of distribution (V/F), and mixed order absorption (first-order and zero-order absorption rate constants with lag times)."( Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects.
Bouchard, S; Fradette, C; Mouksassi, MS; Skinner-Robertson, S; Varin, F, 2015
)
0.42
" This randomised, open-label, crossover study compared the bioavailability of both components after CTC administration under fed and fasting conditions."( The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers.
Encabo, M; Encina, G; Escriche, M; Gascon, N; Lahjou, M; Plata-Salamán, C; Sicard, E; Smith, K; Videla, S, 2018
)
0.48
"As reported for standard-formulation celecoxib, food increased the bioavailability of celecoxib from single-dose CTC."( The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers.
Encabo, M; Encina, G; Escriche, M; Gascon, N; Lahjou, M; Plata-Salamán, C; Sicard, E; Smith, K; Videla, S, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" After a multiple dosage schedule, the serum concentrations of (+)-trans-T, (-)-trans-T, (+)-M1, and (-)-M1 were determined in serum by high performance capillary electrophoresis (HPCE)."( Pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in human subjects.
Hou, YN; Liu, HC; Liu, TJ; Yang, YY, 2001
)
0.54
"An extraction and measurement technique (gas chromatograph equipped with a nitrogen phosphorus detector) was used to measure plasma and brain levels of tramadol and M1 at intervals 10-300 min after oral dosing of tramadol hydrochloride to mice and rats."( Differential tramadol and O-desmethyl metabolite levels in brain vs. plasma of mice and rats administered tramadol hydrochloride orally.
Borenstein, MR; Codd, EE; Coogan, TP; Desai-Krieger, D; Liao, S; Raffa, RB; Stone, DJ; Tao, Q, 2002
)
0.31
" Blood samples were collected prior to dosing and up to 72h after drug intake."( Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.
Bastami, S; Haage, P; Kronstrand, R; Kugelberg, FC; Uppugunduri, S; Zackrisson, AL, 2014
)
0.4
"Decomposed bone and plasma samples of rats exposed to tramadol (TRAM) under different dosing patterns were analyzed."( Analysis of tramadol and O-desmethyltramadol in decomposed skeletal tissues following acute and repeated tramadol exposure by gas chromatography mass spectrometry.
Watterson, JH; Wiebe, TR, 2014
)
0.4
" Based on dosing simulations, a dose of 4 mg/kg q8 hr or q12 hr, on average, may represent an adequate compromise, but further studies are needed using a larger sample size."( PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE AND ITS METABOLITE O-DESMETHYLTRAMADOL FOLLOWING A SINGLE, ORALLY ADMINISTERED DOSE IN CALIFORNIA SEA LIONS (ZALOPHUS CALIFORNIANUS).
Barbosa, L; Boonstra, JL; Cox, SK; Gulland, FM; Johnson, SP; Martin-Jimenez, T; Van Bonn, WG, 2015
)
0.42
" However, dosage adjustments of tramadol are typically not practiced in the clinic when treating patients who are homozygous extensive metabolizers, heterozygous extensive metabolizers, or poor metabolizers."( Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate.
Srinivas, NR, 2015
)
0.42
" In the absence of CYP inhibition (trial A), 20 mg desmetramadol and 50 mg tramadol dosed every 6 hours gave equivalent steady-state (+)-M1, similar adverse events, and analgesia significantly greater than placebo, but equal to each other."( Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials.
Johnson, MS; Kahn, SJ; Maeda, DY; Schuler, AD; Searle, SL; Webster, LR; Zebala, JA, 2019
)
0.51
" Tramadol is dosed at 1-1."( HPLC-UV assay of tramadol and O-desmethyltramadol in human plasma containing other drugs potentially co-administered to participants in a paediatric population pharmacokinetic study.
Hua, AJ; Lim, LY; Nguyen, MN; Salman, S; Tang, EKY; von Ungern Sternberg, BS; Yoo, O, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
alkylbenzeneA monocyclic arene that is benzene substituted with one or more alkyl groups.
ring assemblyTwo or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Tramadol Metabolism Pathway717

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)10.00000.00081.541620.0000AID260241; AID316074
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)7.30000.00010.86458.7096AID260240; AID316073
Mu-type opioid receptorRattus norvegicus (Norway rat)Ki0.01300.00000.38458.6000AID1689583
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)0.04700.00010.813310.0000AID260239; AID316072
Mu-type opioid receptorHomo sapiens (human)Ki0.01090.00000.419710.0000AID1303073; AID1303084; AID410718
Delta-type opioid receptorHomo sapiens (human)Ki6.45000.00000.59789.9300AID1303075; AID410719
Kappa-type opioid receptorHomo sapiens (human)Ki5.22500.00000.362410.0000AID1303077; AID410720
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proteinase-activated receptor 1Homo sapiens (human)EC50 (µMol)0.12000.00370.52341.3000AID669685
Mu-type opioid receptorRattus norvegicus (Norway rat)EC50 (µMol)0.24470.00000.06470.9320AID1689594
Mu-type opioid receptorHomo sapiens (human)EC50 (µMol)0.18000.00000.32639.4000AID1303079; AID669685
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (128)

Processvia Protein(s)Taxonomy
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
connective tissue replacement involved in inflammatory response wound healingProteinase-activated receptor 1Homo sapiens (human)
negative regulation of glomerular filtrationProteinase-activated receptor 1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processProteinase-activated receptor 1Homo sapiens (human)
inflammatory responseProteinase-activated receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayProteinase-activated receptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayProteinase-activated receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProteinase-activated receptor 1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayProteinase-activated receptor 1Homo sapiens (human)
establishment of synaptic specificity at neuromuscular junctionProteinase-activated receptor 1Homo sapiens (human)
positive regulation of cell population proliferationProteinase-activated receptor 1Homo sapiens (human)
negative regulation of cell population proliferationProteinase-activated receptor 1Homo sapiens (human)
response to woundingProteinase-activated receptor 1Homo sapiens (human)
anatomical structure morphogenesisProteinase-activated receptor 1Homo sapiens (human)
platelet activationProteinase-activated receptor 1Homo sapiens (human)
regulation of blood coagulationProteinase-activated receptor 1Homo sapiens (human)
positive regulation of blood coagulationProteinase-activated receptor 1Homo sapiens (human)
positive regulation of cell migrationProteinase-activated receptor 1Homo sapiens (human)
response to lipopolysaccharideProteinase-activated receptor 1Homo sapiens (human)
regulation of interleukin-1 beta productionProteinase-activated receptor 1Homo sapiens (human)
positive regulation of interleukin-6 productionProteinase-activated receptor 1Homo sapiens (human)
positive regulation of interleukin-8 productionProteinase-activated receptor 1Homo sapiens (human)
positive regulation of collagen biosynthetic processProteinase-activated receptor 1Homo sapiens (human)
positive regulation of Rho protein signal transductionProteinase-activated receptor 1Homo sapiens (human)
dendritic cell homeostasisProteinase-activated receptor 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProteinase-activated receptor 1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processProteinase-activated receptor 1Homo sapiens (human)
positive regulation of MAPK cascadeProteinase-activated receptor 1Homo sapiens (human)
negative regulation of neuron apoptotic processProteinase-activated receptor 1Homo sapiens (human)
positive regulation of GTPase activityProteinase-activated receptor 1Homo sapiens (human)
cell-cell junction maintenanceProteinase-activated receptor 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionProteinase-activated receptor 1Homo sapiens (human)
positive regulation of vasoconstrictionProteinase-activated receptor 1Homo sapiens (human)
positive regulation of smooth muscle contractionProteinase-activated receptor 1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProteinase-activated receptor 1Homo sapiens (human)
regulation of synaptic plasticityProteinase-activated receptor 1Homo sapiens (human)
homeostasis of number of cells within a tissueProteinase-activated receptor 1Homo sapiens (human)
release of sequestered calcium ion into cytosolProteinase-activated receptor 1Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProteinase-activated receptor 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProteinase-activated receptor 1Homo sapiens (human)
positive regulation of calcium ion transportProteinase-activated receptor 1Homo sapiens (human)
regulation of sensory perception of painProteinase-activated receptor 1Homo sapiens (human)
platelet dense granule organizationProteinase-activated receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProteinase-activated receptor 1Homo sapiens (human)
thrombin-activated receptor signaling pathwayProteinase-activated receptor 1Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionProteinase-activated receptor 1Homo sapiens (human)
negative regulation of renin secretion into blood streamProteinase-activated receptor 1Homo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
G-protein alpha-subunit bindingProteinase-activated receptor 1Homo sapiens (human)
G protein-coupled receptor activityProteinase-activated receptor 1Homo sapiens (human)
signaling receptor bindingProteinase-activated receptor 1Homo sapiens (human)
protein bindingProteinase-activated receptor 1Homo sapiens (human)
thrombin-activated receptor activityProteinase-activated receptor 1Homo sapiens (human)
G-protein beta-subunit bindingProteinase-activated receptor 1Homo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (36)

Processvia Protein(s)Taxonomy
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneProteinase-activated receptor 1Homo sapiens (human)
extracellular regionProteinase-activated receptor 1Homo sapiens (human)
early endosomeProteinase-activated receptor 1Homo sapiens (human)
late endosomeProteinase-activated receptor 1Homo sapiens (human)
Golgi apparatusProteinase-activated receptor 1Homo sapiens (human)
plasma membraneProteinase-activated receptor 1Homo sapiens (human)
caveolaProteinase-activated receptor 1Homo sapiens (human)
cell surfaceProteinase-activated receptor 1Homo sapiens (human)
platelet dense tubular networkProteinase-activated receptor 1Homo sapiens (human)
neuromuscular junctionProteinase-activated receptor 1Homo sapiens (human)
postsynaptic membraneProteinase-activated receptor 1Homo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1689587Displacement of [3H]-DPDPE from rat delta opioid receptor expressed in CHO cells at 1 uM incubated for 30 mins by liquid scintillation counting method relative to control2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.
AID260242Metabolic stability by incubation with human liver microsomes2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Derivatives of tramadol for increased duration of effect.
AID1303084Displacement of [3H]naloxone from human MOR expressed in CHO-K1 cell membranes after 60 mins by microbeta scintillation counting method2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Discovery of Potent and Selective Agonists of δ Opioid Receptor by Revisiting the "Message-Address" Concept.
AID1689598Agonist activity at rat delta opioid receptor expressed in CHO cells incubated for 1 hr by [35S]GTPgammaS binding based liquid scintillation counting method relative to control2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.
AID316072Binding affinity to mu opioid receptor2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
In vitro and in vivo evaluation of O-alkyl derivatives of tramadol.
AID1689594Agonist activity at rat mu opioid receptor expressed in CHO cells incubated for 1 hr by [35S]GTPgammaS binding based liquid scintillation counting method2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.
AID1303077Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes after 60 mins2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Discovery of Potent and Selective Agonists of δ Opioid Receptor by Revisiting the "Message-Address" Concept.
AID316079Analgesic activity in iv dosed Sprague-Dawley rat assessed as duration of effect by tail-flick model of pain2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
In vitro and in vivo evaluation of O-alkyl derivatives of tramadol.
AID1689596Agonist activity at human kappa opioid receptor expressed in CHO cells incubated for 1 hr by [35S]GTPgammaS binding based liquid scintillation counting method2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.
AID260243Metabolic stability by incubation with human hepatocytes2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Derivatives of tramadol for increased duration of effect.
AID1689595Agonist activity at rat delta opioid receptor expressed in CHO cells incubated for 1 hr by [35S]GTPgammaS binding based liquid scintillation counting method2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.
AID1689588Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells at 1 uM incubated for 30 mins by liquid scintillation counting method relative to control2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.
AID1303073Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Discovery of Potent and Selective Agonists of δ Opioid Receptor by Revisiting the "Message-Address" Concept.
AID410718Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID410721Ratio of Ki for human mu opioid receptor to Ki for human kappa opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID1303079Agonist activity at human MOR expressed in CHO cell membranes after 60 mins by [35S]GTP-gamma-S binding assay2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Discovery of Potent and Selective Agonists of δ Opioid Receptor by Revisiting the "Message-Address" Concept.
AID260241Inhibition of reuptake of Norepinephrine2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Derivatives of tramadol for increased duration of effect.
AID1689583Displacement of [3H]-DAMGO from rat mu opioid receptor expressed in CHO cells incubated for 30 mins by liquid scintillation counting method2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.
AID316073Inhibition of SERT mediated 5-hydroxytryptamine uptake2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
In vitro and in vivo evaluation of O-alkyl derivatives of tramadol.
AID1689597Agonist activity at rat mu opioid receptor expressed in CHO cells incubated for 1 hr by [35S]GTPgammaS binding based liquid scintillation counting method relative to control2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.
AID260239Inhibition of mu opioid receptor2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Derivatives of tramadol for increased duration of effect.
AID1689599Agonist activity at human kappa opioid receptor expressed in CHO cells incubated for 1 hr by [35S]GTPgammaS binding based liquid scintillation counting method relative to control2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.
AID1303075Displacement of [3H]DPDPE from human DOR expressed in CHO cell membranes after 60 mins2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Discovery of Potent and Selective Agonists of δ Opioid Receptor by Revisiting the "Message-Address" Concept.
AID260240Inhibition of reuptake of 5HT2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Derivatives of tramadol for increased duration of effect.
AID410719Displacement of [3H]Naltrindole form human delta opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID410722Ratio of Ki for human delta opioid receptor to Ki for human kappa opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID410720Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID669685Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 1 hr by HTRF assay2012ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3
NOpiates: Novel Dual Action Neuronal Nitric Oxide Synthase Inhibitors with μ-Opioid Agonist Activity.
AID316074Inhibition of NET mediated norepinephrine uptake2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
In vitro and in vivo evaluation of O-alkyl derivatives of tramadol.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (150)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (4.00)18.2507
2000's59 (39.33)29.6817
2010's71 (47.33)24.3611
2020's14 (9.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.48 (24.57)
Research Supply Index5.22 (2.92)
Research Growth Index5.11 (4.65)
Search Engine Demand Index69.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials34 (22.67%)5.53%
Trials0 (0.00%)5.53%
Reviews3 (2.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies4 (2.67%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other109 (72.67%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Validation of a New Method to Detect CYP2D6 Poor Metabolizers by Monitoring Seric Concentrations of O-demethyl-tramadol and Tramadol to Make a Ratio in Comparison With Genotyping in Post-operative Patients Treated With Intravenous Tramadol [NCT00952159]301 participants (Actual)Observational2010-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]